Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
35.91
+0.60 (1.70%)
Nov 5, 2025, 1:49 PM EST - Market open
Harrow Revenue
Harrow had revenue of $63.74M in the quarter ending June 30, 2025, with 30.25% growth. This brings the company's revenue in the last twelve months to $227.66M, up 47.69% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$227.66M
Revenue Growth
+47.69%
P/S Ratio
5.59
Revenue / Employee
$595,971
Employees
382
Market Cap
1.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HROW News
- 9 days ago - Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 - GlobeNewsWire
- 20 days ago - Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other - Seeking Alpha
- 4 weeks ago - ImprimisRx Announces Leadership Changes - GlobeNewsWire
- 5 weeks ago - Harrow, Inc. (HROW) Analyst/Investor Day Transcript - Seeking Alpha
- 5 weeks ago - Harrow to Acquire Melt Pharmaceuticals - GlobeNewsWire
- 5 weeks ago - Harrow Launches Harrow Access for All (HAFA) - GlobeNewsWire
- 7 weeks ago - Harrow Announces Agenda and Speakers for Investor & Analyst Day - GlobeNewsWire
- 7 weeks ago - Harrow: Buy A Blend Of Value And Growth - Seeking Alpha